Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 09, 2022

SELL
$0.32 - $0.67 $4,954 - $10,372
-15,482 Closed
0 $0
Q2 2020

Jul 28, 2020

BUY
$6.67 - $13.58 $64,719 - $131,766
9,703 Added 167.9%
15,482 $210,000
Q1 2019

Apr 29, 2019

SELL
$5.41 - $8.73 $10,998 - $17,748
-2,033 Reduced 26.02%
5,779 $47,000
Q4 2018

Jan 25, 2019

BUY
$5.39 - $9.15 $15,280 - $25,940
2,835 Added 56.96%
7,812 $43,000
Q2 2018

Aug 06, 2018

BUY
$9.15 - $11.34 $26,315 - $32,613
2,876 Added 136.89%
4,977 $50,000
Q1 2018

May 03, 2018

BUY
$9.53 - $15.68 $20,022 - $32,943
2,101 New
2,101 $20,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $342M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.